Skip to content
Screener

Erasca, Inc. ERAS Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.5×+0.3×
Eli Lilly logo
Eli LillyLLY
1.4×+0.1×
Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.4×+0.1×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
11.4×-0.4×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788

FAQ

What is Erasca, Inc.'s current ratio?
Erasca, Inc. (ERAS) reported current ratio of 9.5× in Q1 2026.
How has Erasca, Inc.'s current ratio changed year-over-year?
Erasca, Inc.'s current ratio decreased by 22.9% year-over-year, from 12.4× to 9.5×.
What is the long-term trend for Erasca, Inc.'s current ratio?
Over 5 years (2020 to 2025), Erasca, Inc.'s current ratio has grown at a 2.7% compound annual growth rate (CAGR), from 8.8× to 10×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Erasca, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude